Vertex Pharmaceuticals (VRTX) Share-based Compensation (2009 - 2026)

Vertex Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $166.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation changed 0.18% year-over-year to $166.4 million; the TTM figure through Mar 2026 stood at $686.2 million (up 2.01% YoY), while the FY2025 annual figure was $685.9 million, down 1.8% from the prior year.
• Share-based Compensation was $166.4 million for Q1 2026 at Vertex Pharmaceuticals, up from $157.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $208.6 million in Q4 2023 to a low of $111.5 million in Q4 2022.
• Historically, Share-based Compensation has averaged $154.3 million across 5 years, with a median of $157.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation surged 87.09% in 2023, then dropped 19.56% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $111.5 million in 2022, then surged by 87.09% to $208.6 million in 2023, then decreased by 19.56% to $167.8 million in 2024, then dropped by 6.08% to $157.6 million in 2025, then gained by 5.58% to $166.4 million in 2026.
• The last three Share-based Compensation figures came in at $166.4 million (Q1 2026), $157.6 million (Q4 2025), and $194.9 million (Q3 2025), per Business Quant data.